ESMO Video Commentary - Nivolumab benefit continues in NSCLC

Speaker: Sanjay Popat

CheckMate 017 clearly showed that the checkpoint inhibitor improves the overall health status in patients with advanced squamous non-small cell lung cancer. According to Sanjay Popat of the Royal Marsden Hospital NHS Foundation Trust in London, UK, results from the phase III CheckMate 017 will have a huge impact on clinical practice, wiping out all concerns for potential drug toxicity. Read more...

Discussion Points